交易 Eledon Pharmaceuticals, Inc. - ELDN CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024874% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.002651% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|
Eledon Pharmaceuticals, Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
收入 | |||||
总营业费用 | 36.867 | 18.465 | 16.051 | 14.06 | 13.121 |
销售/一般/行政费用,总计 | 13.132 | 10.052 | 6.056 | 7.243 | 11.099 |
研究与开发 | 23.735 | 6.131 | 8.128 | 6.817 | 2.022 |
营业收入 | -36.867 | -18.465 | -16.051 | -14.06 | -13.121 |
利息收入(费用),非经营净值 | |||||
税前净收入 | -36.86 | -23.215 | -16.011 | -14.065 | -13.116 |
税后净收入 | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
未计算非常项目前的净收益 | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
净收入 | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
普通股股东可获收益 (不含非经常性项目) | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
普通股股东可获收益 (含非經常性項目) | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
摊薄净收入 | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
摊薄后加权平均股 | 14.8196 | 1.45143 | 0.65558 | 0.50034 | 0.25989 |
扣除特别项目的每股摊薄盈利 | -2.32841 | -15.7162 | -24.4227 | -28.111 | -50.4679 |
每股正常摊薄盈利 | -2.32841 | -14.6943 | -21.5748 | -28.111 | -50.4679 |
其他,净值 | 0.007 | -4.75 | 0.04 | -0.005 | 0.005 |
非常规项目总计 | 0 | ||||
异常费用(收入) | 0 | 2.282 | 1.867 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0 |
总营业费用 | 10.598 | 9.283 | 9.859 | 9.385 | 10.506 |
销售/一般/行政费用,总计 | 3.146 | 3.54 | 3.224 | 3.203 | 2.848 |
研究与开发 | 7.452 | 5.743 | 6.635 | 6.182 | 7.658 |
营业收入 | -10.598 | -9.283 | -9.859 | -9.385 | -10.506 |
其他,净值 | 0.127 | 0.036 | -0.005 | 0 | 0.003 |
税前净收入 | -10.471 | -9.247 | -9.864 | -9.385 | -10.503 |
税后净收入 | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
未计算非常项目前的净收益 | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
净收入 | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
普通股股东可获收益 (不含非经常性项目) | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
普通股股东可获收益 (含非經常性項目) | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
摊薄净收入 | -10.471 | -9.247 | -9.864 | -8.806 | -9.817 |
摊薄后加权平均股 | 14.2659 | 14.2659 | 14.3307 | 14.8159 | 14.8159 |
扣除特别项目的每股摊薄盈利 | -0.73399 | -0.64819 | -0.68831 | -0.59436 | -0.6626 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.73399 | -0.64819 | -0.68831 | -0.59436 | -0.6626 |
异常费用(收入) | 0 | 0 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 88.346 | 115.63 | 9.971 | 14.276 | 19 |
现金和短期投资 | 84.833 | 114.195 | 8.791 | 12.972 | 17.233 |
现金等价物 | 84.833 | 114.195 | 8.791 | 12.972 | 17.233 |
短期投资 | |||||
Prepaid Expenses | 3.479 | 1.287 | 0.881 | 0.674 | 1.697 |
Other Current Assets, Total | 0.034 | 0.038 | 0.054 | 0.63 | 0.07 |
Total Assets | 170.548 | 197.185 | 10.931 | 17.026 | 20.892 |
Property/Plant/Equipment, Total - Net | 0.768 | 0.138 | 0.321 | 0.014 | 0.025 |
Property/Plant/Equipment, Total - Gross | |||||
Accumulated Depreciation, Total | |||||
Other Long Term Assets, Total | 0.4 | 0.383 | 0.639 | 0.869 | 0 |
Total Current Liabilities | 4.401 | 2.483 | 1.322 | 2.534 | 1.44 |
Accounts Payable | 1.813 | 1.366 | 0.329 | 0.689 | 0.418 |
Accrued Expenses | 2.588 | 1.117 | 0.993 | 1.845 | 1.022 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.553 | 6.589 | 1.466 | 2.534 | 1.44 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Total Equity | 163.995 | 190.596 | 9.465 | 14.492 | 19.452 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Common Stock | 0.014 | 0.015 | 0.013 | 0.009 | 0.007 |
Additional Paid-In Capital | 278.88 | 270.974 | 67.034 | 56.054 | 46.951 |
Retained Earnings (Accumulated Deficit) | -114.899 | -80.393 | -57.582 | -41.571 | -27.506 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 170.548 | 197.185 | 10.931 | 17.026 | 20.892 |
Total Common Shares Outstanding | 14.3068 | 15.1604 | 0.72047 | 0.52349 | 0.39505 |
Goodwill, Net | 48.648 | 48.648 | 0 | 1.867 | 1.867 |
应收账款总额,净额 | 0 | 0.11 | 0.245 | ||
Other Liabilities, Total | 0.4 | 0 | 0.144 | ||
Intangibles, Net | 32.386 | 32.386 | |||
Deferred Income Tax | 1.752 | 4.106 | |||
Total Preferred Shares Outstanding | 0.11427 | 0.10807 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 79.325 | 88.346 | 95.558 | 102.582 | 110.241 |
现金和短期投资 | 76.677 | 84.833 | 94.041 | 101.133 | 108.579 |
现金等价物 | 76.677 | 84.833 | 94.041 | 101.133 | 108.579 |
应收账款总额,净额 | 0 | 0 | 0.087 | 0.197 | |
Prepaid Expenses | 2.631 | 3.479 | 1.506 | 1.351 | 1.439 |
Other Current Assets, Total | 0.017 | 0.034 | 0.011 | 0.011 | 0.026 |
Total Assets | 161.378 | 170.548 | 177.17 | 184.305 | 191.682 |
Property/Plant/Equipment, Total - Net | 0.675 | 0.768 | 0.222 | 0.267 | 0.092 |
Goodwill, Net | 48.648 | 48.648 | 48.648 | 48.648 | 48.648 |
Intangibles, Net | 32.386 | 32.386 | 32.386 | 32.386 | 32.386 |
Other Long Term Assets, Total | 0.344 | 0.4 | 0.356 | 0.422 | 0.315 |
Total Current Liabilities | 2.958 | 4.401 | 4.046 | 2.677 | 4.206 |
Accounts Payable | 1.026 | 1.813 | 1.598 | 0.857 | 1.514 |
Accrued Expenses | 1.932 | 2.588 | 2.448 | 1.82 | 2.692 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.06 | 6.553 | 6.422 | 5.784 | 7.811 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 1.752 | 1.752 | 2.331 | 3.017 | 3.605 |
Total Equity | 156.318 | 163.995 | 170.748 | 178.521 | 183.871 |
Common Stock | 0.014 | 0.014 | 0.014 | 0.014 | 0.014 |
Additional Paid-In Capital | 281.067 | 278.88 | 276.827 | 274.783 | 272.749 |
Retained Earnings (Accumulated Deficit) | -124.763 | -114.899 | -106.093 | -96.276 | -88.892 |
Total Liabilities & Shareholders’ Equity | 161.378 | 170.548 | 177.17 | 184.305 | 191.682 |
Total Common Shares Outstanding | 13.7568 | 14.3068 | 14.3068 | 14.3066 | 14.3066 |
Total Preferred Shares Outstanding | 0.12417 | 0.11427 | 0.11427 | 0.11427 | 0.11427 |
Other Liabilities, Total | 0.35 | 0.4 | 0.045 | 0.09 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | -34.506 | -22.811 | -16.011 | -14.065 | -13.116 |
经营活动产生的现金 | -28.913 | -15.212 | -13.857 | -11.893 | -14.941 |
经营活动产生的现金 | 0 | 0.005 | 0.009 | 0.011 | 0.022 |
非现金物品 | 8.099 | 8.178 | 3.348 | 1.543 | 0.628 |
营运资金的变化 | -0.152 | -0.18 | -1.203 | 0.618 | -2.475 |
投资活动产生的现金 | 0 | 11.035 | 0 | 23.258 | |
资本支出 | |||||
其他投资现金流量项目,总计 | 0 | 11.035 | 0 | 23.258 | |
融资活动产生的现金 | -0.449 | 109.581 | 9.676 | 7.562 | 7.869 |
融资现金流项目 | -0.45 | -0.025 | |||
股票的发行(报废),净额 | 0.001 | 109.606 | 9.676 | 7.562 | 7.869 |
债务的发行(退还),净额 | |||||
现金净变化 | -29.362 | 105.404 | -4.181 | -4.331 | 16.186 |
Deferred Taxes | -2.354 | -0.404 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -9.864 | -34.506 | -25.7 | -15.883 | -8.499 |
Cash From Operating Activities | -8.156 | -28.913 | -19.705 | -12.612 | -5.166 |
Cash From Operating Activities | 0 | 0 | 0 | 0 | |
Deferred Taxes | 0 | -2.354 | -1.775 | -1.089 | -0.501 |
Non-Cash Items | 2.279 | 8.099 | 5.985 | 3.898 | 1.82 |
Changes in Working Capital | -0.571 | -0.152 | 1.785 | 0.462 | 2.014 |
Cash From Financing Activities | 0 | -0.449 | -0.449 | -0.45 | -0.45 |
Financing Cash Flow Items | 0 | -0.45 | -0.45 | -0.45 | -0.45 |
Issuance (Retirement) of Stock, Net | 0.001 | 0.001 | 0 | 0 | |
Net Change in Cash | -8.156 | -29.362 | -20.154 | -13.062 | -5.616 |
Cash From Investing Activities | 0 | 0 | |||
Other Investing Cash Flow Items, Total | 0 | 0 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
BVF Partners L.P. | Hedge Fund | 16.9132 | 2326710 | 0 | 2022-12-31 | LOW |
ALS Therapy Development Institute | Corporation | 9.6359 | 1325585 | 0 | 2022-03-31 | LOW |
Cormorant Asset Management, LP | Hedge Fund | 8.853 | 1217882 | -5618 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.9398 | 679557 | 314 | 2022-12-31 | LOW |
Woodline Partners LP | Hedge Fund | 3.7558 | 516675 | 0 | 2022-12-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 3.4338 | 472383 | 0 | 2022-09-30 | LOW |
Ensign Peak Advisors, Inc. | Foundation | 3.2202 | 443001 | 355715 | 2022-12-31 | LOW |
CM Management, LLC | Investment Advisor | 1.7068 | 234800 | -10200 | 2022-12-31 | MED |
Ikarian Capital LLC | Hedge Fund | 1.6125 | 221830 | 0 | 2022-12-31 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9388 | 129151 | -314 | 2022-12-31 | LOW |
ACCI Capital Investments SGIIC, SA | Investment Advisor | 0.4361 | 60000 | 0 | 2022-12-31 | LOW |
JMAC Enterprises LLC | Investment Advisor | 0.3964 | 54538 | 0 | 2022-12-31 | LOW |
Ingalls & Snyder LLC (Asset Management) | Investment Advisor/Hedge Fund | 0.3696 | 50849 | -300 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.3569 | 49095 | 532 | 2022-12-31 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.3434 | 47237 | -24700 | 2022-12-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3249 | 44692 | 0 | 2022-12-31 | LOW |
SVB Financial Group | Holding Company | 0.2952 | 40613 | 40613 | 2022-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2185 | 30053 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.2157 | 29673 | -2200 | 2022-12-31 | HIGH |
Boothbay Fund Management, LLC | Investment Advisor/Hedge Fund | 0.1603 | 22050 | 0 | 2022-12-31 | HIGH |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Eledon Pharmaceuticals, Inc. Company profile
关于 Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals, Inc.是一家处于临床阶段的生物制药公司。 公司专注于为需要器官或细胞移植的自身免疫性疾病患者或肌萎缩性侧索硬化症(ALS)患者开发药物。 公司的主要候选产品AT-1501是一种人源化单克隆抗体(mAb),旨在靶向CD40配体(CD40L),也叫CD154,是一种表达在人类免疫系统T细胞表面的分子。 CD40或CD40L信号在产生促炎症反应中的核心作用使其成为治疗干预自身免疫性疾病、诱导和维持移植耐受和神经炎症的候选药物。 阻断CD40L通路的激活可以防止多种动物物种的急性和长期异体移植排斥反应,并改善自身免疫和ALS的临床前模型的疾病进展和病理情况。
Industry: | Bio Therapeutic Drugs |
19900 MacArthur Blvd Ste 550
IRVINE
CALIFORNIA 92612-8426
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。